McAllister-Williams R Hamish, Baldwin David S, Cantwell Roch, Easter Abby, Gilvarry Eilish, Glover Vivette, Green Lucian, Gregoire Alain, Howard Louise M, Jones Ian, Khalifeh Hind, Lingford-Hughes Anne, McDonald Elizabeth, Micali Nadia, Pariante Carmine M, Peters Lesley, Roberts Ann, Smith Natalie C, Taylor David, Wieck Angelika, Yates Laura M, Young Allan H
1 Institute of Neuroscience, Newcastle University, Newcastle, UK.
2 Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
J Psychopharmacol. 2017 May;31(5):519-552. doi: 10.1177/0269881117699361. Epub 2017 Apr 25.
Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.
对于临床医生以及有心理健康问题的女性而言，孕期使用精神药物的决策始终是一项挑战，这是由于疾病本身对母亲和胎儿/婴儿的风险、孕期药物的有效性以及子宫内接触药物或通过母乳对胎儿/婴儿造成的风险存在不确定性。这些共识指南旨在就这些问题提供实用建议。它们分为以下几个部分：孕期未治疗疾病的风险；围产期用药的一般原则；与个别药物相关的益处和危害；以及特定疾病管理的建议。
